SCHEMBL2087980

SCHEMBL2087980

OB(O)Oc1ccc(Cl)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.48
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KMO O15229 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
AHR P35869 1/20 0.39
TP53 P04637 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HAO1 Q9UJM8 1/20 0.38
KDM4E B2RXH2 2/20 0.38
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
MRGPRX4 Q96LA9 1/20 0.36
CYP3A4 P08684 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28006279 0.98 HSP90AA1 (0.47) HSP90AA1SLC6A2SLC6A4SLC6A3HSD17B10
SCHEMBL30536637 0.83 HSD17B10 (0.46) HSP90AA1HSD17B10SMN1; SMN2ALDH1A1LMNA
SCHEMBL30988470 0.83 HSD17B10 (0.46) HSP90AA1HSD17B10KDM4EALDH1A1CYP3A4
SCHEMBL27925365 0.83 HSD17B10 (0.46) HSP90AA1HSD17B10SMN1; SMN2ALDH1A1LMNA
SCHEMBL7934079 0.81 HSP90AA1 (0.47) HSP90AA1SLC6A2SLC6A4SLC6A3HSD17B10
SCHEMBL740211 0.81 SOS1 (0.44) SLC6A4HSD17B10SMN1; SMN2MEN1KMT2A
SCHEMBL30506427 0.81 SOS1 (0.44) SLC6A4HSD17B10SMN1; SMN2MEN1KMT2A
SCHEMBL31505704 0.81 CA12 (0.47) HSP90AA1SMN1; SMN2TP53MEN1KMT2A
SCHEMBL3367275 0.81 PPARG (0.42) HSP90AA1SLC6A4KMT2APPARGPPARA
SCHEMBL30844891 0.81 PPARG (0.42) HSP90AA1SLC6A4KMT2APPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1506176-B1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PFIZER ITALIA SRL (IT) 2013-04-24 EP claimed
EP-1444981-A1 INTRACELLULAR CALCIUM CONCENTRATION INCREASE INHIBITORS Mikoshiba, Katsuhiko (JP) 2004-08-11 EP claimed
US-12497392-B2 EP300/CBP inhibitor HINOVA PHARMACEUTICALS INC. (CN) 2025-12-16 US disclosed
CN-117142949-A Biphenyl 3CL protease inhibitor and preparation method and application thereof 上海应用技术大学 2023-12-01 CN disclosed
CN-117126151-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-28 CN disclosed
CN-117069713-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-17 CN disclosed
CN-117069712-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-17 CN disclosed
CN-117024420-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-10 CN disclosed
CN-114051496-B Derivative compounds for introducing biphenyl into novel amino alkanoic acids and antifungal pharmaceutical compositions containing the same 阿米蒂比奥有限公司 2023-08-04 CN disclosed
US-20230027088-A1 EP300/CBP INHIBITOR HINOVA PHARMACEUTICALS INC. (CN) 2023-01-26 US disclosed
EP-4043458-A1 EP300/CBP INHIBITOR Hinova Pharmaceuticals Inc. (CN) 2022-08-17 EP disclosed
EP-0675118-B1 Biphenylderivatives, process for their preparation and their use as medicaments EISAI CO LTD (JP) 2002-10-09 EP disclosed
EP-1140896-A1 BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5 Takeda Chemical Industries, Ltd. (JP) 2001-10-10 EP disclosed
EP-1137641-A1 PROCESS FOR PREPARING PYRIDAZIN-3-ON DERIVATIVES SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2001-10-04 EP disclosed
US-6281214-B1 USEFUL FOR TREATING AND AMELIORATING MENTAL DISORDERS EISAI CO., LTD (JP) 2001-08-28 US disclosed
US-6235771-B1 AIDS THERPAY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-05-22 US disclosed
WO-2000037455-A1 BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5 TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2000-06-29 WO disclosed
EP-1010690-A1 BIARYLALKYLENECARBAMIC ACID DERIVATIVES AND BACTERIOCIDES FOR AGRICULTURAL AND HORTICULTURAL USE KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 2000-06-21 EP disclosed
WO-2000034249-A1 PROCESS FOR PREPARING PYRIDAZIN-3-ON DERIVATIVES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2000-06-15 WO disclosed
EP-0675118-A2 Biphenylderivatives, process for their preparation and their use as medicaments Eisai Co., Ltd. (JP) 1995-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12497392-B2 EP300/CBP inhibitor EP300, MLLT1, CREBBP HSP90AA1 2111/4885SLC6A2 4800/4885SLC6A4 4628/4885
US-20230027088-A1 EP300/CBP INHIBITOR EP300, MLLT1, CREBBP HSP90AA1 2111/4885SLC6A2 4800/4885SLC6A4 4628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.